Cotización Sanofi - SAN

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Último Precio

90.60

Postura de Compra

90.59

Postura de Venta

90.61

Volume Operado de la Acción

169,486

90.21 Rango del Día 90.94

83.28 Rango de 52 semanas 106.14

Capitalización de Mercado [m]

113.489B

Precio Anterior

90.80

Precio de Apertura

90.44

Hora

90.6

Última hora de negociación

04:10:22

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

1,551,907

Acciones en circulación

1,252,640,466

Rendimiento del Dividendo

12.23%

Ratio Precio/Utilidad

21.02

Beneficio por acción (BPA)

4.31

turnover

43.07B

Beneficio neto

5.4B

Sector

Health & Allied Services,nec

Industria

Pharmaceutical Preparations

Sitio web

www.sanofi.com

Sede

Paris, Paris, Fra

Fundado

1994

Sanofi is listed in the Health & Allied Services sector of the Euronext with ticker SAN. The last closing price for Sanofi was 90.80 €. Over the last year, Sanofi shares have traded in a share price range of 83.28 € to 106.14 €.

Sanofi currently has 1,252,640,466 shares in issue. The market capitalisation of Sanofi is 113.74 € billion. Sanofi has a price to earnings ratio (PE ratio) of 21.02.

Sanofi: Information concerning the total number of voting rights and shares - October 2024

Sanofi: Information concerning the total number of voting rights and shares - October 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L...

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II...

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria...

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive...

Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée

Communiqué de presse : La FDA a accepté l’examen de la sBLA pour le Dupixent dans le traitement de l’urticaire chronique spontanée La FDA a accepté l’examen de la sBLA pour le Dupixent dans le...

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Sarclisa recommended for EU approval by the CHMP to treat...

Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué non éligible à une greffe

Communiqué de presse : Sarclisa : approbation recommandée par le CHMP dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué non éligible à une greffe Sarclisa : approbation...

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination...

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Dupixent approved in the EU as the first and only medicine for young...

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-2.76	-2.95629820051	93.36	94.4	90.17	1814250	91.84798828	DE
4	-7.81	-7.93618534702	98.41	101.9	90.17	1631654	95.74355537	DE
12	-10.04	-9.97615262321	100.64	106.14	90.17	1551907	100.27061623	DE
26	1.03	1.14993859551	89.57	106.14	85.94	1488487	96.10824111	DE
52	5.6	6.58823529412	85	106.14	83.28	1452003	92.81723408	DE
156	1.21	1.35361897304	89.39	106.66	76.45	1759780	92.49180759	DE
260	8.34	10.1385849745	82.26	106.66	67.65	1956228	89.3084835	DE

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
BIDSGascogne DS	0.0028 € (55.56%)	40.05k
ATODSAtos SE	0.005 € (21.95%)	12.61M
ALMASMastrad	0.01 € (16.28%)	2.11M
SOISOITEC	73.65 € (15.98%)	207.86k
ALEMVEmova Group	0.89 € (11.25%)	13
EBUSEbusco Holding NV	0.92 € (-24.96%)	1.57M
VACBSPierre & Vacances	0.048 € (-14.29%)	427
EMGDSEuromedis DS	0.0088 € (-12.00%)	5.17k
ALVETTheraVet SA	0.0804 € (-10.67%)	28.93k
ALAIRGroupe Airwell	1.43 € (-9.49%)	1.57k
ATODSAtos SE	0.005 € (21.95%)	12.61M
ALTDTonner Drones	0.0102 € (10.87%)	9.28M
BCPBanco Comercial Portugues SA	0.4386 € (-0.27%)	8.47M
ALVERVergnet	0.0048 € (0.00%)	8.19M
ALNEVNeovacs	0.0002 € (0.00%)	3.38M